Click-Engineered, Bioresponsive, and Versatile Particle-Protein-Dye System.
active targeting
bioresponsive
multifunctional
photodynamic therapy
protein/nanoparticle conjugate
Journal
ACS applied bio materials
ISSN: 2576-6422
Titre abrégé: ACS Appl Bio Mater
Pays: United States
ID NLM: 101729147
Informations de publication
Date de publication:
19 Aug 2019
19 Aug 2019
Historique:
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
We present a multifunctional polymer based nanoparticle platform for personalized nanotheranostic applications, which include photodynamic therapy and active targeting. In this system, poly(propargyl acrylate) (PA) particles were surface-modified with organic ligands and fluorophores (the payload) through an environmentally-sensitive linker. An azide modified bovine serum albumin (azBSA) was employed as the linker. This system prevents opsonization and, upon digestion, releases the payload. Attachment of the emitting payload to the particle through azide-modified bovine serum albumin (BSA) quenches emission, which can be again activated with digestion of the azBSA. The emission "turn-on" at a specific location will increase the signal-to-noise ratio. By utilizing human head and neck squamous carcinoma cells (UMSCC22A), photodynamic therapy studies with these particles gave promising reductions in cell growth. Additionally, the particle-protein-dye system is versatile as different fluorophores (such as silicon phthalocyanine or cyanine 3) can be attached to the protein and the same activation/deactivation behavior is observed. Active targeting can be employed to enhance the concentration of the payload in the designated tumor. Human lung carcinoma cells (A549) were utilized in toxicity studies where PA-azBSA particles were modified with a Survivin targeting ligand and indicated an enhanced cell death with the modified particles relative to the "free" Survivin targeting ligand.
Identifiants
pubmed: 31844845
doi: 10.1021/acsabm.9b00025
pmc: PMC6913539
mid: NIHMS1061861
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3183-3193Subventions
Organisme : NCI NIH HHS
ID : R01 CA119079
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Bioorg Med Chem Lett. 2013 Oct 1;23(19):5429-33
pubmed: 23968825
Anal Chim Acta. 2009 Sep 21;650(2):151-9
pubmed: 19720186
Pharm Res. 2012 Jan;29(1):1-34
pubmed: 21913032
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
pubmed: 17092599
Eur J Med Chem. 2010 Jan;45(1):90-7
pubmed: 19836860
Nat Rev Cancer. 2003 Jan;3(1):46-54
pubmed: 12509766
Oncogene. 2003 Nov 24;22(53):8581-9
pubmed: 14634620
J Proteome Res. 2005 Sep-Oct;4(5):1569-74
pubmed: 16212408
Org Lett. 2012 Oct 19;14(20):5290-3
pubmed: 23039069
Pharm Res. 2007 Jan;24(1):1-16
pubmed: 17109211
J Am Chem Soc. 2006 May 10;128(18):6024-5
pubmed: 16669657
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7667-71
pubmed: 23127889
Nature. 1998 Dec 10;396(6711):580-4
pubmed: 9859993
J Immunol Methods. 2002 May 1;263(1-2):57-74
pubmed: 12009204
J Am Chem Soc. 2011 Jun 22;133(24):9242-5
pubmed: 21627118
Nat Nanotechnol. 2007 Aug;2(8):469-78
pubmed: 18654343
ACS Nano. 2012 Jul 24;6(7):5866-79
pubmed: 22725248
Nano Lett. 2006 Nov;6(11):2427-30
pubmed: 17090068
Anal Chem. 2010 Dec 15;82(24):10045-51
pubmed: 21087034
Bioorg Med Chem Lett. 2007 Jun 1;17(11):3122-9
pubmed: 17391963
Nat Rev Cancer. 2006 Jul;6(7):535-45
pubmed: 16794636
Adv Mater. 2009 Nov 20;21(43):4348-52
pubmed: 26042942
J Mater Chem B. 2013 Sep 28;1(36):4542-4554
pubmed: 32261197
Mol Cancer Ther. 2006 May;5(5):1087-98
pubmed: 16731740
Science. 2012 Nov 16;338(6109):903-10
pubmed: 23161990
Macromol Biosci. 2011 Jul 7;11(7):927-37
pubmed: 21480531
Langmuir. 2014 May 13;30(18):5209-16
pubmed: 24716818
Methods. 2000 Sep;22(1):4-23
pubmed: 11020313
Clin Cancer Res. 2013 Feb 1;19(3):631-42
pubmed: 23251006
J Org Chem. 2003 Jan 24;68(2):609-12
pubmed: 12530893
Angew Chem Int Ed Engl. 2011 Sep 12;50(38):8794-804
pubmed: 21905176
Chem Commun (Camb). 2006 Sep 21;(35):3705-7
pubmed: 17047818
Angew Chem Int Ed Engl. 2009;48(5):872-97
pubmed: 19142939
Toxicol Appl Pharmacol. 1992 Aug;115(2):147-55
pubmed: 1641848
J Proteome Res. 2010 Oct 1;9(10):5422-37
pubmed: 20722421
Pharm Res. 2012 Apr;29(4):902-21
pubmed: 22274559
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286
Drug Discov Today. 2003 Dec 15;8(24):1112-20
pubmed: 14678737
Nanoscale. 2016 Dec 8;8(48):20066-20073
pubmed: 27892586
Biophys J. 1975 Feb;15(2 Pt 1):137-41
pubmed: 1167468
Nanotechnology. 2012 Apr 6;23(13):135701
pubmed: 22417878
Farmaco. 1999 Apr 30;54(4):195-201
pubmed: 10384712
Chem Commun (Camb). 2005 Sep 7;(33):4172-4
pubmed: 16100593